Alexandra Straus

Dr. Alexandra Straus

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Journal of Lipid Research
Verified
Journal Article
Open access
ASAlexandra Straus
Alexandra Straus
GMGrace Mavodza
Grace Mavodza
CSCan E. Senkal
Can E. Senkal
Sphingolipids play key roles in membrane structure and cellular signaling. Ceramide synthase (CerS)-generated ceramide is implicated in cellular stress responses and induction of apoptosis. Ceramide and other sphingolipids are linked to the induction of ER stress response pathways. However, the mechanisms by which ceramide modulates ER stress signaling are not well understood. Here, we show that the ER stress inducer brefeldin A (BFA) causes increased glycosylation of CerS6, and that treatment with BFA causes increased endogenous ceramide accumulation. To our surprise, we found that CerS6 activity was not affected by BFA-induced glycosylation. Instead, our data show that basal glycosylation of CerS6 at Asn18 is required for CerS6 activity. We used a robust HCT116 CRISPR-Cas9 CerS6 KO with reintroduction of either WT CerS6 or a mutant CerS6 with a point mutation at asparagine-18 to an alanine (N18A) which abrogated glycosylation at that residue. Our data show that cells stably expressing the N18A mutant CerS6 had significantly lower activity in vitro and in situ as compared to WT CerS6 expressing cells. Further, the defective CerS6 with N18A mutation also had defects in GSK3 beta, AKT, JNK, and STAT3 signaling. Despite being required for CerS6 activity, Asn18 glycosylation did not influence ER stress response pathways. Overall, our study provides vital insight into the regulation of CerS6 activity by posttranslational modification at Asn18 and identifies glycosylation of CerS6 to be important for ceramide generation and regulation of downstream cellular signaling pathways.

6 December 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
SKSachin K. Kempelingaiah
Sachin K. Kempelingaiah
ASAlexandra Straus
Alexandra Straus
GMGrace Mavodza
Grace Mavodza
CSCan E. Senkal
Can E. Senkal
Iron is an essential element required for critical processes, such as oxygen transport, energy generation, and DNA synthesis. To be incorporated as a cofactor, iron that is stored in the cytosol within ferritin needs to be liberated by ferritinophagy. Ferritinophagy is an autophagic process in which ferritin is targeted to the lysosomes, through its interaction with nuclear receptor coactivator 4 for degradation and release of labile iron. Despite its involvement in neurodegenerative diseases, anemia, cancer, and insulin resistance, a specific and sensitive method to detect ferritinophagy has been lacking. To detect and quantitate ferritinophagic flux, we generated a Halo-tagged ferritin heavy chain 1 (FTH1) construct and took advantage of stabilization of Halo fragment in the presence of its fluorescently labeled ligand. Stably expressed Halo-FTH1 operated identical to its endogenous counterpart. More importantly, using pulse-chase settings, lysosomal accumulation of Halo fragment after induction of ferritinophagy was detected and quantitated by in-gel fluorescence, immunoblotting, and microscopic analyses. Finally, we found that silencing of nuclear receptor coactivator 4 prevented accumulation of tetramethylrhodamine-Halo fragment and degradation of endogenous FTH1 under ferritinophagic conditions, confirming the specificity of our assay. Together, the HaloTag-FTH1 tool we generated can be used to specifically detect and quantitate ferritinophagy in mammalian cells with a fluorescent Halo ligand, and this approach can be instrumental in studies focusing on cellular iron metabolism.

20 July 2026 in Cancers
Verified
Journal Article
Open access
PDF file
SAShady Azzam
Shady Azzam
ASAlexandra Straus
Alexandra Straus
CSCan Senkal
Can Senkal
DSDevanand Sarkar
Devanand Sarkar
Background/Objectives: Hepatocellular carcinoma (HCC) is undergoing a profound epidemiological shift from viral etiologies toward metabolic dysfunction-associated steatohepatitis (MASH). Current targeted therapies often fail to provide effective responses due to the complex, interconnected nature of the tumor microenvironment. This review aims to explain the molecular axis linking chronic metabolic injury to carcinogenesis, focusing specifically on the oncoproteins Astrocyte elevated gene-1/metadherin (AEG-1/MTDH) and staphylococcal nuclease and tudor domain-containing 1 (SND1) as cooperating regulators of this disease network. Methods: This article represents a narrative review of the published literature and does not follow a systematic or exhaustive search protocol. A structured literature search using specific search terms was conducted across PubMed, Scopus, and Web of Science databases, with a last search date of May 2026. Results: Available preclinical data indicate that AEG-1 mediates early preneoplastic injury via dysregulation of hepatic lipid metabolism leading to lipotoxicity and survival of genetically unstable hepatocytes. As the disease progresses, AEG-1 amplifies NF-κB-driven inflammation and, as tumors emerge, recruits SND1 as a cooperating partner to form a gene-silencing complex that suppresses tumor suppressor proteins. Furthermore, AEG-1 and SND1 reprogram surrounding macrophages into an immunosuppressive state and drive tumor resistance to standard anti-angiogenic and chemotherapeutic drugs. Conclusions: The evidence reviewed supports a model in which HCC is driven by an interconnected metabolic-inflammatory-oncogenic cycle. AEG-1 functions as an upstream metabolic and inflammatory driver that cooperates with SND1 in a subset of oncogenic silencing events within this pathogenic network. Therefore, utilizing advanced nanomedicine platforms to simultaneously target these proteins represents a mechanistically rational therapeutic strategy that warrants further preclinical evaluation in advanced HCC.